In addition, PARP inhibitors, such as talazoparib [14], rucaparib [15], niraparib [16], and olaparib [17] have been approved in for the treatment of the aforementioned cancers with BRCA1/2 mutation by the United States Food and Drug Administration. Here, BRCA1 is linked to cancer.